Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
Trial details
- Registry ID
- NCT04642638
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 ExposureNCT04642638 | Inovio Pharmaceuticals | Phase 2, Phase 3 | Terminated | 2022-09-13Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |